IL-17/IL-23 Pathway
Th17 cells are activated by IL-1β, IL-6, IL-23, and TGF-β via the STAT3 pathway, producing IL-17A/F and IL-22. The IL-17/IL-23 axis is the dominant immune pathway in psoriasis, identified around 2005 and driving the development of targeted…
1 sources - 0 claims
Th17 cells are activated by IL-1β, IL-6, IL-23, and TGF-β via the STAT3 pathway, producing IL-17A/F and IL-22. The IL-17/IL-23 axis is the dominant immune pathway in psoriasis, identified around 2005 and driving the development of targeted biologic therapies. The net immune result in psoriasis is excessive Th1 and Th17 activity combined with insufficient Treg activity. T-regulatory cells are under-activated in psoriasis, failing in their normal function of suppressing inflammation and maintaining immune tolerance.